The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine

Seyyed-Hossein Yahyazadeh-Jabbari; Nasser  Malekpour; Bahram  Salmanian; Hossein Foodazi; Masoud Salehi; Farsad Noorizadeh

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine

Author(s):

Seyyed-Hossein Yahyazadeh-Jabbari¹,

Nasser Malekpour²,

Bahram Salmanian^3,*,

Hossein Foodazi⁴,

Masoud Salehi⁵,

Farsad Noorizadeh²

1Clinical Research Center, Milad Hospital; Dept. of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran

2Clinical Research Center, Milad Hospital, Tehran, Iran

3Clinical Research Center, Milad Hospital; Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4Dept. of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran

5Clinical Research Center, Milad Hospital; Dept. of Statistics and Mathematics, School of Health Management and Information Sciences, Tehran University of Medical Sciences, Tehran, Iran

International Journal of Cancer Management:Vol. 6, issue 3; e80420

Published online:Sep 30, 2013

Article type:Research Article

Received:Apr 09, 2013

Accepted:May 14, 2013

How to Cite:Seyyed-Hossein Yahyazadeh-JabbariNasser MalekpourBahram SalmanianHossein FoodaziMasoud SalehiFarsad Noorizadehet al.The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine.Int J Cancer Manag.6(3):e80420.

Abstract

Background: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different preoperative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients.

Methods: Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate.

Results: Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response.

Conclusion: Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy.

Keywords

Fulltext

The Full text is available in PDF.

comments